文献速递神经肿瘤

TWEAK受体Fn14在IDH1野生型与突变型胶质瘤中的差异表达

Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
PubMed 文献 · J Neurooncol · 2018-02-16

本研究比较了IDH1野生型(WT)与突变型(R132H)胶质瘤中TWEAK受体Fn14的表达。低级别和高级别(即GBM)IDH1 R132H胶质瘤的Fn14 mRNA和蛋白水平均低于IDH1 WT胶质瘤。在胶质瘤细胞中强制过表达IDH1 R132H可降低Fn14表达,而用IDH1 R132H抑制剂AGI-5198或DNA去甲基化剂5-aza-2'-脱氧胞苷处理可提高Fn14表达。

要点

  • IDH1 R132H低级别和高级别(即GBM)胶质瘤的Fn14 mRNA和蛋白水平低于IDH1 WT胶质瘤。
  • 强制过表达IDH1 R132H可降低胶质瘤细胞的Fn14表达。
  • AGI-5198或5-aza-2'-脱氧胞苷处理IDH1 R132H过表达细胞可提高Fn14表达。

核心结论

  • 结果支持Fn14在IDH1 WT肿瘤相关的更具侵袭性和侵袭性表型中发挥作用。
  • IDH1 R132H突变型胶质瘤中Fn14基因低表达可能源于DNA甲基化改变所致的表观遗传调控。

研究设计与样本

  • 研究比较了IDH1野生型(WT)与突变型(R132H)胶质瘤及过表达IDH1 R132H酶的工程细胞系中Fn14基因的表达。
  • 世界卫生组织基于异柠檬酸脱氢酶1(IDH1)基因突变状态对人间胶质瘤进行了组织病理学重新分类。

主要发现

  • 低级别和高级别(即GBM)IDH1 R132H胶质瘤的Fn14 mRNA和蛋白水平均低于IDH1 WT胶质瘤。
  • 在胶质瘤细胞中强制过表达IDH1 R132H蛋白可降低Fn14表达。
  • 用IDH1 R132H抑制剂AGI-5198或DNA去甲基化剂5-aza-2'-脱氧胞苷处理IDH1 R132H过表达细胞可提高Fn14表达。
  • 既往报道间充质和 proneural GBM转录组亚型分别表达最高和最低水平的Fn14 mRNA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The TNF receptor superfamily member Fn14 is overexpressed by many solid tumor types, including glioblastoma (GBM), the most common and lethal form of adult brain cancer. GBM is notable for a highly infiltrative growth pattern and several groups have reported that high Fn14 expression levels can increase tumor cell invasiveness. We reported previously that the mesenchymal and proneural GBM transcriptomic subtypes expressed the highest and lowest levels of Fn14 mRNA, respectively. Given the recent histopathological re-classification of human gliomas by the World Health Organization based on isocitrate dehydrogenase 1 (IDH1) gene mutation status, we extended this work by comparing Fn14 gene expression in IDH1 wild-type (WT) and mutant (R132H) gliomas and in cell lines engineered to overexpress the IDH1 R132H enzyme. We found that both low-grade and high-grade (i.e., GBM) IDH1 R132H gliomas exhibit low Fn14 mRNA and protein levels compared to IDH1 WT gliomas. Forced overexpression of the IDH1 R132H protein in glioma cells reduced Fn14 expression, while treatment of IDH1 R132H-overexpressing cells with the IDH1 R132H inhibitor AGI-5198 or the DNA demethylating agent 5-aza-2'-deoxycytidine increased Fn14 expression. These results support a role for Fn14 in the more aggressive and invasive phenotype associated with IDH1 WT tumors and indicate that the low levels of Fn14 gene expression noted in IDH1 R132H mutant gliomas may be due to epigenetic regulation via changes in DNA methylation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hersh DS, Peng S, Dancy JG, et al. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. J Neurooncol. 2018. PMID: 29453678. doi:10.1007/s11060-018-2799-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。